Iovance Biotherapeautics(IOVA.US)

Last Updated 19:00:00 ET
longbridge loading

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

Tip Ranks·
US
IOVA
+2.31%
Tip Ranks·
US
IOVA
+2.31%

Iovance Biotherapeautics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 71.43 M

Earnings Watch·
US
IOVA
+2.31%
Earnings Watch·
US
IOVA
+2.31%

Top 10 US Stock Gainers (5.4)

Top Gainers&Losers·
US
GBTG
-0.11%
US
CRCL
+0.53%
US
CELC
+7.16%
Top Gainers&Losers·
US
GBTG
-0.11%
US
CRCL
+0.53%
US
CELC
+7.16%

CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA

Market Beat·
US
IOVA
+2.31%
US
BIB
+4.98%
US
IBBQ
+2.43%
Market Beat·
US
IOVA
+2.31%
US
BIB
+4.98%
US
IBBQ
+2.43%

Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?

Simplywall·
US
IOVA
+2.31%
US
PBE
+1.60%
US
IBB
+2.27%
Simplywall·
US
IOVA
+2.31%
US
PBE
+1.60%
US
IBB
+2.27%

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News

StockTitan·
US
IOVA
+2.31%
US
BBH
+0.96%
US
PBE
+1.60%
StockTitan·
US
IOVA
+2.31%
US
BBH
+0.96%
US
PBE
+1.60%
© 2026 Longbridge｜Disclaimer